Jackson Andrew C. 4
4 · Calidi Biotherapeutics, Inc. · Filed Sep 5, 2025
Insider Transaction Report
Form 4
Jackson Andrew C.
Chief Financial Officer
Transactions
- Award
Stock Options (right to buy)
2025-09-03+30,000→ 30,000 totalExercise: $1.58From: 2025-09-03Exp: 2035-09-03→ Common stock (30,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on September 3, 2025 (the "Grant Date"), the Reporting Person was granted 30,000 incentive stock options (the "Options") at an exercise price of $1.58, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 9/03/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.